3 days of carefully curated sessions gathered 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC) and Regulations to overcome the industry’s largest and critical bottlenecks, such as:

• Adopting effective & novel viral platforms & employing a critical selection of transgene
• Revolutionizing the delivery of OV’s through employing next-generation IT carrier Cells
• Ensuring improved CMC, GMP Manufacturing, and adherence to regulatory standards
• Selecting combination therapies to guarantee OV candidates are streamlined through clinic

Also, join us for a dedicated pre-conference day on approaches for advancing OV candidates through the clinic, towards optimizing manufacturing and clinical trial design. This Focus Day unites the oncolytic virotherapy community to discuss and share their current progress and understanding of optimizing their clinical studies and manufacturing strategies. Experts from academia and industry will share their insights, experiences, and best practices. Topics of discussion will include viral vector design, analytical methods for product characterization, viral vector stability, raw material management and regulatory considerations. Take part in this deep-dive focus day and hear from the leading minds as they take us through valuable clinical data, for you to take back to your team.

Join the only end-to-end forum dedicated to emerging OV immunotherapies and contribute to driving the next wave of clinical approvals and towards a landscape of more effective anti-cancer drugs generating anti-tumour immune response within patients in need.